One of the highest priorities in the field of Parkinson’s disease (PD) is the development of early and preclinical diagnosis. Michael Ugrumov, MD, PhD, Koltzov Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia, describes different studies evaluating potential biomarkers of PD in body fluids. Various studies have identified biomarkers in the CSF and tears of patients with PD. More recently, Prof. Ugrumov published a study searching for biomarkers in the blood of patients at risk of developing PD at the prodromal stage. This interview took place at the 17th World Congress on Controversies in Neurology (CONy) in Dubrovnik, Croatia.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.